ClinicalTrials.gg
CompletedNCT06758583Updated May 6, 2025

A Trial Comparing Pharmacokinetics, Safety and Tolerability of Two Subcutaneous Concentrations of Dapiglutide

A Phase 1 interventional study of Dapiglutide 7.5 mg in Overweight and Obesity, sponsored by Zealand Pharma. Completed at 1 site in Germany. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-06.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Zealand Pharma · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 336 studies in Obesity with a site in Germany — 73 open to participants now, 108 under way, 47 of them phase 3. Obesity · Germany.

Enrollment
244th of 274
30 · median 156
Started
2024
with 21 others
Phase 1
43 of 336
9 open now
Registered
250th of 336
by date

Among the 336 studies in Obesity with a site in Germany, this one is the 244th largest by enrollment of the 274 interventional ones that give a count, is one of 22 that started in 2024, is one of 43 in phase 1, and was the 250th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

73 of the 336 studies in Obesity with a site in Germany are open now. Recruiting first, the newest first:

68 more — sign in →

All 73 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 336 studies in Obesity with a site in Germany, or all of them as a file.
02

Study summary

This is a phase 1, open-label, single-center, randomized, parallel-group trial designed to investigate the pharmacokinetic profiles, safety, and tolerability of a single dose administration of 7.5 mg dapiglutide administered s.c. with two drug product concentrations, 10 mg/mL and 25 mg/mL. The trial will be conducted in participants with a BMI ≥ 27.0 kg/m2.

Read the detailed description

Dapiglutide is a dual Glucagon-like peptide-1-/Glucagon-like peptide-2 Receptor Agonist (GLP-1R/GLP-2RA) in clinical development for weight management. The purpose of this phase 1 trial is to compare pharmacokinetics (PK) of a single dose administration of 7.5 mg dapiglutide administered subcutaneously (s.c.) with two drug product concentrations, 10 mg/mL and 25 mg/mL and will be conducted in 30 participants with a body mass index (BMI) ≥ 27.0 kg/m2. The development of a drug product with higher drug concentration will facilitate investigation of a wider dose range of dapiglutide in the clinical development program of the compound. The PK profile of a weight management drug should be assessed in people with a wide range of BMI and with a BMI within the range of the target population as body weight is expected to influence PKs of dapiglutide.

03

Conditions studied

  • Overweight and Obesity

Browse trials for

Keywords

  • GLP-1R/GLP-2RA
  • overweight
  • obesity
  • weight management
04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

This study's enrollment of 30 is below the median of 67 across 9,016 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Zealand Pharma is the lead sponsor of 43 studies on the registry; 5 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 8 (47%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 64 years, both inclusive,
  • >= 27.0 kg/m\^2
  • \< 6.5 %.

Exclusion criteria

Exclusion Criteria:

  • Any history or presence of a disorder or a disease, which, in the investigator's opinion, might jeopardize participant's safety, evaluation of results or compliance with the protocol, treatment with dapiglutide (any exposure) or any other drugs, including dual and tri agonists, involving a GLP-1 RA or GLP-2 RA within 180 days prior to screening.
  • Any medication (prescription and non-prescription drugs) with the exception of stable treatment with antihypertensive and lipid-lowering drugs as well as thyroid replacement therapy.
  • Female participants of who are not willing to use highly effective until 42 days after dosing
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Dapiglutide 10 mg/mL

    Single dose, s.c. administration

    Drug: Dapiglutide 7.5 mg

  • Experimental
    Dapiglutide 25 mg/mL

    Single dose, s.c. administration

    Drug: Dapiglutide 7.5 mg

Interventions

  • Single dose administration of 7.5 mg dapiglutide administered s.c. with two drug product concentrations, 10 mg/mL and 25 mg/mL.

07

What researchers measure

Primary outcomes

  1. To compare pharmacokinetics of a single dose administration of 7.5 mg dapiglutide

    Area under the dapiglutide plasma concentration-time curve from time zero to infinity after a single 7.5 mg dose of dapiglutide (AUC0-inf).

    Time frame: Trial Day 1 to 28

  2. To compare pharmacokinetics of a single dose administration of 7.5 mg dapiglutide

    Maximum observed dapiglutide plasma concentration after a single 7.5 mg dose of dapiglutide (Cmax)

    Time frame: Trial Day 1 to 28

Secondary outcomes

  1. To characterize the pharmacokinetic profiles of a single dose administration of 7.5 mg dapiglutide

    Area under the dapiglutide plasma concentration-time curve from time zero to last measurable concentration after a single 7.5 mg dose of dapiglutide (AUC0-t)

    Time frame: Day 1 to 28

  2. To characterize the pharmacokinetic profiles of a single dose administration of 7.5 mg dapiglutide

    Time to maximum observed dapiglutide plasma concentration after a single 7.5 mg dose of dapiglutide (Tmax)

    Time frame: Day 1 to 28

  3. To characterize the pharmacokinetic profiles of a single dose administration of 7.5 mg dapiglutide

    Terminal elimination half-life for dapiglutide after a single 7.5 mg dose of dapiglutide (t½)

    Time frame: Day 1 to 28

  4. To characterize the pharmacokinetic profiles of a single dose administration of 7.5 mg dapiglutide

    Elimination rate constant for dapiglutide after a single 7.5 mg dose of dapiglutide (λz)

    Time frame: Day 1 to 28

  5. To characterize the pharmacokinetic profiles of a single dose administration of 7.5 mg dapiglutide

    Apparent clearance of dapiglutide after a single 7.5 mg dose of dapiglutide (CL/F)

    Time frame: Day 1 to 28

  6. To characterize the pharmacokinetic profiles of a single dose administration of 7.5 mg dapiglutide

    Apparent volume of distribution during terminal phase of dapiglutide after a single 7.5 mg dose of dapiglutide (Vz/f)

    Time frame: Day 1 to 28

  7. To characterize the pharmacokinetic profiles of a single dose administration of 7.5 mg dapiglutide

    Mean residence time of dapiglutide after a single 7.5 mg dose of dapiglutide (MRT)

    Time frame: Day 1 to 28

  8. To investigate the safety and tolerability of a single dose administration of 7.5 mg dapiglutide

    Incidence of treatment emergent adverse events (TEAEs) from dosing (Day 1) to end of trial (Day 42).

    Time frame: Day 1 to 42

08

Study locations

1 site
  • Profil Institut für Stoffwechselforschung GmbH
    Neuss, North Rhine-Westphalia 41460, Germany
09

References and documents

Individual participant data

Plan to share: No — The data collection and handling of clinical trial data at the trial site has been designed to limit the possibility of identifying trial subjects from their data. To this end, pseudonymised data will be used wherever possible and the collection of demographic information that could be used for re-identification of subjects will be restricted to the extent necessary for the conduct of this trial.

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Apr 2025, 3 months.

Of 334 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 3 months is below that.

Counting every sponsor, half of 439 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2024
First posted
Jan 6, 2025
StartActual
Dec 23, 2024
Primary completionActual
Apr 12, 2025
CompletionActual
Apr 25, 2025
Last update
May 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06758583
Lead sponsor
Zealand Pharma
Responsible party
Sponsor
First posted
Jan 6, 2025
Start date
Dec 23, 2024
Primary completion
Apr 12, 2025
Completion
Apr 25, 2025
Last update
May 6, 2025

Study contacts

Ulrike Hoevelmann, MD
principal investigator · Profil, Neuss

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapiglutide

Start the discussion